louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06435338: Patient Decision Aid Tool for HPV Vaccination Among Adults Ages 27-45 Years Old
Official title: Patient Decision Aid Tool for HPV Vaccination Among Adults Ages 27-45 Years Old
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Decision Aid
Hpv
Lead sponsor: The University of Texas Health Science Center at San Antonio
Sponsor class: OTHER
Collaborators: name: University of North Texas Health Science Center
name: University of South Florida
name: Temple University
name: Indiana University School of Medicine
name: Merck Sharp & Dohme LLC
First posted: 2024-05-30
Enrollment: 632
Sex: ALL
Minimum age (years): 27
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this study is to learn if a patient decision tool for HPV vaccination works for decision-making among adults ages 27-45. Researchers will compare a web-based patient decision tool to an information sheet to see if the tool works for decision-making. Participants will take a baseline survey, view the intervention or control condition, and then take a follow-up survey.


Eligibility criteria: Inclusion Criteria:

* Unvaccinated for HPV
* 27-45 years
* Resides in the United States
* Reads English
* Consents to participate

Exclusion Criteria:

* none

Primary outcomes:
measure: Decisional conflict - 16 item scale
timeFrame: Immediate post-test
measure: Decisional conflict - 4 item scale
timeFrame: Immediate post-test
Secondary outcomes:
measure: Knowledge
timeFrame: Immediate post-test
measure: Intentions
timeFrame: Immediate post-test
measure: Decision
timeFrame: Immediate post-test
measure: Perceived expectation
timeFrame: Immediate post-test
measure: Perceived risk
timeFrame: Immediate post-test
measure: Decision self-efficacy
timeFrame: Immediate post-test
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: UT School of Public Health San Antonio
state: Texas
Study officials:
References:
citation: O'Connor AM. User Manual - Decisional Conflict Scale (16 item question format). Ottawa: Ottawa Hospital Research Institute. 1993. http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf
citation: Legare F, Kearing S, Clay K, Gagnon S, D'Amours D, Rousseau M, O'Connor A. Are you SURE?: Assessing patient decisional conflict with a 4-item screening test. Can Fam Physician. 2010 Aug;56(8):e308-14.
citation: O'Connor AM. User Manual - Decision Self-Efficacy Scale. Ottawa: Ottawa Hospital Research Institute. 1993. http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decision_SelfEfficacy.pdf
citation: Garg A, Wheldon CW, Galvin AM, Moore JD, Griner SB, Thompson EL. The Development and Psychometric Evaluation of the Mid-adult Human Papillomavirus Vaccine Knowledge Scale in the United States. Sex Transm Dis. 2022 Jun 1;49(6):423-428. doi: 10.1097/OLQ.0000000000001615. Epub 2022 Feb 8.
Clinical trial NCT02948738: Asthma Inpatient Research on Education
Official title: Asthma Inpatient Research on Education: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthmatic Attack
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Sponsor class: OTHER
First posted: 2016-10-28
Enrollment: 140
Sex: ALL
Minimum age (years): 2
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Children with asthma are admitted for asthma attacks very frequently in the U.S. The families and children are given basic education about asthma but studies are needed to improve this education so that it makes a meaningful difference in health outcomes and asthma care. This study compares two inpatient education models for children hospitalized with asthma.

Detailed description: The current standard is to review an asthma action plan with families and to review inhaler medication administration. In this study, investigators will be assigning families to either a control (current standard education) or and intervention group. In the intervention group, participants will receive interactive education based on learning theories that are thought to enhance long term memory. Participants in the interactive group will build their own action plan using colored templates and pictures. Participants will also learn to use their inhaler using teach-back methodologies. Investigators will then compare the two groups in terms of ER visits, hospitalizations, family confidence in managing asthma, asthma knowledge, and quality of life.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of asthma

Exclusion Criteria:

* Active Cardiac Disease
* Speaks language other than English or Spanish

Primary outcomes:
measure: ER visits
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Ann and Robert H. Lurie Childrens Hosptial of Chicago
state: Illinois
Study officials:
affiliation: Northwestern University and Lurie Children's Hospital
name: Waheeda Samady, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04266938: Impact of Rapid ART Initiation on Retention in Care in the Southern US
Official title: Impact of Rapid ART Initiation on Retention in Care in the Southern US
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: HIV-1-infection
Lead sponsor: University of Louisville
Sponsor class: OTHER
First posted: 2020-02-12
Enrollment: 258
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: OTHER

Brief summary: Impact of Rapid ART Initiation on Retention in Care in the Southern US

Specific Goals and Aims:

The major goal for this study is to determine if rapid start of antiretroviral (ART) therapy increases retention in HIV medical care. The investigators hypothesize that there will be an increase in retention in care with rapid start, by removing barriers that would normally delay enrollment in a treatment program and enforce the importance of linkage to care and ART initiation from diagnosis.

In order to test this hypothesis, the investigators have the following specific aims for their proposed study:

1. Study retention in care after rapid ART start in comparison to standard of care.
2. Analyze risk factors for decreased retention in care, with focus on high-risk populations.
3. Analyze potential demographic and geographic determinants of retention in care.
4. Generate retention in care data in a Southern US state.

The investigators hypothesize the introduction of rapid start ART, as well as the introduction of care navigators, will lead to improved clinical outcomes, including retention in care at one year, viral suppression at one year, time to viral suppression, and time to first missed appointment. In the event rapid start ART fails to have a positive impact on clinical outcomes, the results of this study will still positively contribute to the knowledge gap, since there is a scarcity of data in the Southern United States, specifically in high-risk populations, such as racial and ethnic minorities, youth, and patients co-infected with hepatitis C.


Eligibility criteria: Inclusion Criteria:

* Prospective arms: Human subjects ≥18 years old, newly diagnosed with HIV who are establishing care at the 550 Clinic.
* Retrospective arm: Human subjects ≥18 years old, newly diagnosed with HIV who established care at the 550 Clinic and were treated with ART between 2012-2019.

Exclusion Criteria:

* Pregnancy
* Prior HIV diagnosis or exposure to ART
* Medical necessity for therapy with ART agent other than bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), such as drug allergy, drug-drug interactions, creatinine clearance \<30.

Primary outcomes:
measure: Retention in Care
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Louisville
country: United States
facility: 550 Clinic
state: Kentucky
Study officials:
References:
Clinical trial NCT03065738: Effect of RO On GB During TKR Severe Varus Deformity
Official title: Effect Of Reduction Osteotomy On Gap Balancing During Total Knee Replacement For Severe Varus Deformity
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Genu Varum
Knee Osteoarthritis
Keywords: reduction osteotomy
knee arthroplasty
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-02-28
Enrollment: 30
Sex: ALL
Minimum age (years): 55
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Effect Of Reduction Osteotomy On Gap Balancing During Total Knee Replacement For Severe Varus Deformity

Detailed description: Severe varus deformity with a tibio femoral angle of 15° or more as measured on full-length weight-bearing radiographs necessitates extensive release of the medial structures to gain neutral limb alignment during total knee arthroplasty (TKA). progressive releases of the medial structures are performed until medial and lateral envelopes are equally balanced. This technique, however, faces a risk of over-release and subsequent instability, ultimately resulting in the use of a thicker polyethylene insert or even a constrained-type prosthesis. Reduction osteotomy is known as a soft tissue-sparing technique for soft tissue balancing, and it is capable of reducing the amount of release required to balance the knee and of preventing over release of medial structures. Dixon et al . and Mullaji et al . proposed the effectiveness of down-sizing the tibial component in the case of knees with severe varus deformity Aim of the work: Assess the effect of reduction osteotomy on gab balancing during total knee arthroplasty for severe varus deformity -What is the amount of deformity correction achieved with reduction osteotomy during TKA in varus knees? - What is the correlation of amount of deformity correction achieved to the amount of bone osteotomized and the degree of varus deformity?

Eligibility criteria: Inclusion Criteria:

* Patients with severe varus deformity more than 15 degrees (long film-mechanical axis)
* Patients with bone defect of medial tibial condyle

Exclusion Criteria:

* Patients with extra-articular deformity
* Patients with valgus deformity

Primary outcomes:
measure: HKA angle
timeFrame: immediate post operative
Secondary outcomes:
measure: functional outcome by knee society score
timeFrame: one year follow up
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University School of medicine Vice Dean for Research and Post-Graduate Studies
Study officials:
affiliation: Assiut University
name: Hatem Bakr, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00984438: Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
Official title: Phase I/II Trial for Patients With Recurrent Resectable Glioblastoma Multiforme Using Surgery With Implantable BCNU Polymer Followed by Post-operative Irinotecan and Bevacizumab
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Glioblastoma Multiforme
Lead sponsor: University of Cincinnati
Sponsor class: OTHER
Collaborators: name: Eisai Inc.
First posted: 2009-09-25
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to try and identify a more effective treatment plan to improve survival rates for patients with a recurrent Glioblastoma Multiforme (GBM) brain tumor that can be removed by brain surgery.

The study will record what effects (good and bad) the combination of surgery with chemotherapy wafers inserted in the spot where the patient's tumor was during your surgery and post-operative chemotherapy has on the patient and their survival rate over the next 12 months.


Eligibility criteria: Inclusion Criteria:

* Histopathologically proven diagnosis of GBM in the past with MRI findings compatible with disease recurrence. Multifocal disease is permitted.
* Must have had prior treatment with standard doses of Temodar
* KPS \>50; ECOG \<3
* Predicted life expectancy of \> 3 months
* Study entry must be within 5 weeks of surgical resection

Exclusion Criteria:

* Prior exposure to VEGF inhibitors or Irinotecan
* Intracranial bleed as defined by CT or MRI less than 6 months prior to entry
* GI bleed less than 6 months prior to entry
* Uncontrolled concurrent illness that would limit compliance with study requirements

Primary outcomes:
measure: To assess disease free survival
timeFrame: 6 and 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: University of Cincinnati
state: Ohio
Study officials:
affiliation: University of Cincinnati
name: Margie Gerena-Lewis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06861738: Effect of Parcetamol in Headach
Official title: Comaring the Effect of Paracetamol in Tratment of Headach
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Headache
Keywords: paracetamol
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2025-03-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Tension-type headache (TTH) affects about 1 person in 5 worldwide. It is divided into infrequent episodic TTH (fewer than one headache per month), frequent episodic TTH (two to 14 headaches per month), and chronic TTH (15 headache days a month or more). Paracetamol (acetaminophen) is one of a number of analgesics suggested for acute treatment of headaches in frequent episodic TTH.Objectives To assess the efficacy and safety of paracetamol for the acute treatment of frequent episodic TTH in adults.

Detailed description: Headaches are a commonly reported problem in community-based surveys worldwide. The lifetime prevalence of headache is estimated to be greater than 90% , and the annual prevalence rate is estimated to be 46% in the general adult population . Variations in reported prevalence may result from differences in study design, population, inclusion or exclusion of cases of infrequent episodic TTH, overlap with probable migraine, cultural and environmental differences, or even genetic factors . TTH is more common than migraine, a finding replicated across the work.

The management of people with headaches is largely neglected , and may be fragmented by the involvement of clinicians from different medical specialities (neurology; ear, nose and throat; ophthalmology; psychiatry). Because headache is rarely life-threatening and headache pain is generally mild to moderate in intensity, people often self medicate and do not seek formal care from health services .

Headache can be either primary (no underlying cause) or secondary (due to other systemic or local causes) . TTH belongs to the group of primary headaches and is seen in nearly one-third of people experiencing headaches; the large number of people affected imposes a significant burden on the healthcare system. Generally, episodes of TTH are mild to moderate in intensity, and self limiting, but in a small group of people they may be more severe and disabling . People with longer lasting or more severe headaches may seek help in a clinical setting, but the majority of people do not do so, resulting often in inadequate and inappropriate management .

Eligibility criteria: Inclusion Criteria:

* both sex
* 18 years old to 65 years
* free ct brain

Exclusion Criteria:

* migrane
* any brain pathology

Primary outcomes:
measure: pain score VAS score
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04315038: Metabolomics Profiling Research of Human Cerebrospinal Fluid in Aging Process
Official title: Metabolomics Profiling and Biomarker Research of Human Cerebrospinal Fluid in Aging Process and Age-related Neurodegenerative Diseases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aging
Metabolites
Neurodegenerative Diseases
Keywords: Aging
cerebrospinal fluid
metabolomics
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2020-03-19
Enrollment: 190
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with received spinal anesthesia and had written informed consent

Brief summary: Perform quantitative metabolomics on human cerebrospinal fluid (CSF) samples and establish the first human CSF Metabolome Database of aging process in Taiwan.

Detailed description: Metabolomics is new science based on metabolite profiles in biofluids and tissues, which under bioinformatics approaches and analyses could help to characterize metabolomic status of CSF in aging process. In this prospective study, the investigators plan to enroll 200 health volunteers and 40 neurodegenerative diseases patients with received operation under spinal anesthesia. Blood and CSF samples will be analyzed using hydrogen-1 nuclear magnetic resonance (1H-NMR) and lipid chromatography-mass spectrometry (LC-MS).

Eligibility criteria: Inclusion Criteria:

Aging groups:

1. . Above 20 years.
2. . No history of central nerve system injury and neurologic illness
3. . ASA≦II
4. . Written informed consent from the patient

Aged-related neurodegenerative diseases group:

1. . Above 60 years of age
2. . Medical record proved the history of Parkinsonism or Alzheimer disease
3. . ASA≦III
4. . Written informed consent from the patient or guardian by statute.

Exclusion Criteria:

1. patient refuses to sign informed consent
2. patients with coagulopathy, systemic infective disease and severe liver and renal function impairment
3. patients with spine or brain tumor and CNS disease
4. the presence of severe and/or uncontrolled and/or unstable medical disease within 12 months prior to study (e.g. acute pancreatitis, stroke, liver cirrhosis, congestive heart failure, and systemic immune disorder etc
5. Concurrent participation or planning to participate in another interventional clinical trial (Concurrent participation in an observational trial allowed)

Primary outcomes:
measure: Exam metabolic profiles of CSF in aging process and age-related neurodegenerative diseases
timeFrame: An average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Taoyuan
country: Taiwan
facility: Chang Gung Memorial Hospital
Study officials:
References:
Clinical trial NCT06782438: Evaluation of an Artificial Intelligence Algorithm Reducing Noise on Fast Whole-body Bone Tomoscintigraphy Acquisitions Recorded by a 360 Degree Cadmium-Zinc-Tellurid Camera
Official title: Evaluation of an Artificial Intelligence Algorithm Reducing Noise on Fast Whole-body Bone Tomoscintigraphy Acquisitions Recorded by a 360 Degree Cadmium-Zinc-Tellurid Camera
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Bone Scan
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2025-01-17
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who had a whole-body thee dimensions bone scan for rheumatological or oncological indications and non opposed to th use of their data

Brief summary: Recently, artificial intelligence algorithms reducing noise by deep learning have been developed with application to SPECT and PET images.

Many studies have reported the possibility of reducing the recording time in bone scintigraphy by applying artificial intelligence algorithms reducing noise

Detailed description: Only two studies compared images denoised by a Deep Learning algorithm to those denoised by conventional filters (Gaussian and median filters). The first study was conducted only on patients, without phantom analysis and without taking into account the size of the lesions. The second study included an analysis on phantom and patients, but with application to planar images rather than to SPECT images that are increasingly used today

The hypothesis of our study conducted on phantom and patients is that an artificial intelligence algorithm reducing noise could replace the conventional filters usually used in bone SPECT for the denoising of scintigraphic images.

Eligibility criteria: Inclusion Criteria:

Patients who had a whole-body thee dimensions bone scan for rheumatological or oncological indications.

Exclusion Criteria:

Patients opposed to the use of their data

Primary outcomes:
measure: To compare imaging treated by the intelligence artificial algorithm with imaging treated with the traditionnal filter artificial algorithm
timeFrame: one day
Secondary outcomes:
Other outcomes:
Locations:
city: Vandoeuvre les Nancy cedex
country: France
facility: Nuclear Medicine Department
Study officials:
References:
Clinical trial NCT01156038: Atopy Patch Test in Normal Population : Pilot Study
Official title: Atopy Patch Test in Normal Population : Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Normal
Keywords: Atopy patch test
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2010-07-02
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Atopy patch test in normal population

Detailed description: The initial diagnostic work up of suspected food allergy includes patient's history, skin prick test (SPT), measurement of food specific immunoglobulin E (IgE) with serological assays, and more recently the atopy patch test. A positive SPT seems to reflect early reactions to food challenges, whereas the atopy patch test has a high diagnostic efficacy for late phase clinical reactions. The purpose of this study was to evaluate atopy patch test reaction in non-atopic population.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteer
* Age 18-40 yrs
* Volunteer sign for informed consent

Exclusion Criteria:

* who have dermographism
* who have chronic disease eg.autoimmune disease, immune deficiency, cancer or allergic disease
* pregnant women
* who have severe eczema
* who receive antihistamine, topical steroid and systemic steroid \> 20 mg/day within 7 days prior study

Primary outcomes:
measure: Reaction of atopy patch test
timeFrame: 3 days
Secondary outcomes:
measure: Comparisons atopy patch test reaction between lyophilized allergen and commercial allergen
timeFrame: 3 days
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Department of Pediatrics, Siriraj hospital, Mahidol University
Study officials:
affiliation: Mahidol University
name: Nualanong Visitsunthorn, Professor
role: STUDY_DIRECTOR
References: